Stephen Berenson - 01 Jul 2025 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Reporting relationship: Director
Issuer ticker: MCRB
Reported as of: 01 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2025, 17:38:55 UTC
Prior SEC filing: 11 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Thomas J. DesRosier, Attorney-in-Fact

Key filing fact

Stephen Berenson filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 02 Jul 2025.

Key facts

This page summarizes Stephen Berenson's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2025, 17:38.

Change

Previous filing in this sequence was filed on 11 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001760671 Primary reporting owner

Berenson Stephen

Relationship: Director
Address: C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Signature: /s/ Thomas J. DesRosier, Attorney-in-Fact
Signature date: 02 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MCRB transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +11,470
Change %
Price: $0.000000
Shares after: 11,470
Date: 01 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,470
Exercise price: $10.71
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2025, January 1, 2026, April 1, 2026, and July 1, 2026, provided that if the issuer's 2026 annual meeting of stockholders occurs before July 1, 2026, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date.